The Uromigos: Recent Episodes
The Uromigos
Brian hosts a panel at Uromigos Live 2024 in Nashville with Michael Morris, Tanya Dorff and Karen Autio
Tom moderates a live panel of Kala Sridhar, Shilpa Gupta, Andrea Apolo and Petros Grivas on the emerging ADC data in bladder cancer
Tom and Brian finish discussing ESMO 2024 highlights. Even without a guest Tom still interrupts a lot.
Fresh of the Presidential session address, Tom discusses his data with Petros commenting.
Arun Azad describes thisrandomised phase II study of sequential 177Lu-PSMA-617 and docetaxel vs. docetaxel in mHSPC
Matt Galsky describes his ESMO 2024 abstract of disitimab vedotiin + pembrlizumab in bladder cancer
Lothar Bergmann describes this investigator-initiated trial of Ipi/Nivo vs SOC in Non-clear Cell RCC
Brad McGregor joins Brian and Tom to discuss a new HIF inhibitor, NKT2152, and preliminary data in RCC
Silke joins Brian and Tom to discuss upcoming data in prostate, bladder and kidney cancer in Barcelona at ESMO 2024
Nima Sharifi joins Brian and Tom to discuss mechanisms of resistance to hormone therapy in prostate cancer
Ira Mellman delves into the update of this classic paper and the components of an effective anti-tumor immune response.
Maria, Christina and Elena discuss recent changes to the ESMO guidelines in kidney, bladder and prostate cancer.
Naomi Haas joins Tom and Brian in New York City at the World GU Conference to discuss several RCC topics
Eric Jonasch, Co-Chair of the NCCN RCC Guidelines, gives insight into the process of guideline modification and discusses updates in adjuvant, front-line and refractory RCC
Jonathan Rosenberg and a surprise guest discuss comorbidities and treatment-related side effects.
David Braun divides immune therapies into four groups and describes how novel treatments and targets work. Tom and Brian are both excited and, at times, sceptical.
Escuche nuestro primer podcast sobre los aspectos más destacados de ASCO en cáncer de vejiga, riñón y próstata
Axel Bex, Christian Blank, Laura Mertens and Micheil Van der Heijden answer a range of relevant and sometimes irrelevant questions
Viktor Gruenwald, Boris Hadaschik and Gunhild Von Amsberg answer questions around GU cancer and German football
Silke Gillessen joins Tom and Brian, who give their opinion on the data and new 'Take Home Message' format.
Nobuaki Matsubara, Hiroshi Kitamura and Yuji Miura battle through the sometimes ridiculous questions set by Tom and Brian.
David McDermott discusses the adjuvant vs neoadjuvant immune therapy trial and its wider implications.
Guru Sonpavde describes the efficacy of chemotherapy with nivolumab in lymph node only 1st line UC patients. Tom describes the QOL data for EV pembro.
Laurence Albiges discusses this circulating biomarker which may be predictive and prognostic.
Toni Choueiri and Brian describe similarities and differences in the biomarker findings of these two trials. Debate about the value and future of this approach breaks out.
Jonathan Rosenberg gets to grips with the data available for the bladder cohort from the TDXD Destiny pan-tumour cohort.
Alex Wyatt describes the predictive resistance of ctDNA fraction at baseline in predicting outcome.
Christos Kyriakopoulos describes the outcome of this study, where cabazitaxel with abiraterone as combined with abiraterone alone in docetaxel refractory CRPC.
Danny Heng, Christian Kollmannsberger and Kala Sridhar answer questions in an attempt to get to Nashville and take on LA to win the Uromigos Cup.
Nick James discusses this paper, which covers broad issues in prostate cancer - including diagnosis and treatment with a focus on the future.
David Penson discusses highlights for the upcoming meeting. He articulates his excitement around the NMIBC data.
Silke covers key aspects of the meeting, including surgery vs RT, genetic and somatic testing, PSMA imaging and 1st line triplet therapy.
Chris Sweeney is joined by Matt Smith, Anthony Joshua and Lisa Horvath to discuss the management of these complex issues in advanced prostate cancer.
Thomas Suter and Chuck Ryan discuss identification and management of cardiovascular disease for patients starting therapy for prostate cancer.
In this second part, Matt Galsky describes the OS signal data. We also look into the future.
Tom, Brian and Matt Galsky review the screening component of this study, presented at EAU24.
Michiel Van der Heijden explores the role of radiotherapy and other neoadjuvant and other neoadjuvant combinations to prevent the need for surgery.
Matt Galsky describes his phase 2 study looking at gem/cis/nivo followed by nivo in responders. This potentially avoids cystectomy.
FDA Deputy Oncology Director Dan Suzman described approaches to oncology trials. Tom asks 3 last questions which annoys Brian more than usual.
Tanya Dorff describes acapatamab, a prostate-specific membrane antigen (PSMA) CD3 bispecific engager.
Vania Wisdom, editor of the Lancet, talks about approaches to cancer treatment and research in developing countries
Dana Rathkopf describes phase 1 data for the androgen receptor ligand-directed degrader in prostate cancer
Cris Bergerot describes her modifications of existing QOL models while Tom describes the QOL data from LS005
Misha Beltran describes the activity of this novel agent in neuroendocrine prostate cancer.
Silke Gillessen and Betrand Tombal discuss the questions which will address this issue in Lugano in March 2024.
Elena Castro, Begoña Valerrama y Cristina Suárez analizan lo más destacado del cáncer en urología en 2023
Kala Sridhar discusses all the key trials in 2023. She also reveals her favourite Xmas song.
Tom and Brian apologise for the unacceptable words and images which were broadcast by hackers during the Uromigos livestream last week. We’re really sorry and will do everything we can to make sure it never happens again.
Monty Pal, Toni Chouieri, and Tian Zhang join Tom and Brian to discuss CONTACT-03, TiNivo-2, IO-based therapy, and more.Recorded live at Uromigos Live & Unplugged 2023 in Nashville, TN.
Brian is joined by Neeraj Agarwal, Tanya Dorff, Rana McKay, and Michael Morris to review the state of radioligand therapy. The panel examines primary and secondary end points of VISION, current practice patterns, the right way to dose 177Lu-PSMA, PSMAfore, and more.Recorded live at Uromigos Live & Unplugged 2023 in Nashville, TN.
Tom is joined by Sam Chang, Sia Daneshmand, and Petros Grivas to discuss new therapies in non-muscle invasive bladder cancer, including those for BCG-refractory NMIBC and the cretostimogene + pembrolizumab combo for BCG-unresponsive NMIBC. Recorded live at Uromigos Live & Unplugged 2023 in Nashville, TN.
Brian and Tom discuss the benefits and risks of participating in the upcoming meeting . Uncertainty around it’s success are highlighted . Methods of attending remain opaque.
Kevin Kelly described a Six-transmembrane epithelial antigen of the prostate 1 (STEAP1) bispecific T cell engager showing activity in a phase 1 trial in prostate cancer.
Toripalimab plus axitinib as first-line treatment option for advanced RCC by Xinan Sheng
Lisa Pickering discusses the 2 randomised trial and the 1st line combination study in renal cancer
Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)
Nick James discusses the optimal patients for radiotherapy and his approach to perioperative hormone therapy
We describes progress in system therapy for advanced papillary RCC. Opportunities and challenges around personalised therapy are discussed
Susan Slovin describes her JCO investigator initiated R2 study which show the addition of cabazitaxel to abiraterone may be of benefit in CRPC
Celeste shares her thoughts on her career in the lab, collaboration and working with clinicians. She also talks about things that went well and things that went less wells
Jim Catto defends the virtues of cystectomy after last weeks radiotherapy for MIBC podcast with Ananya
Ananya Choudhury discussed the evidence for RT/TMT instead of surgery in muscle invasive bladder cancer. Regina Barragan-Carrillo (Golden Ticket Winner) introduces the podcast.
Chana discusses her role at the FDA, how it functions and answers questions on topical issues.
Laurence Albiges discusses biomarker studies, new combinations and new therapies which were covered in the KCRS23 meeting in the ‘new studies' session.
Neeraj Agarwal describes the TALAPRO-2 study and relevance of the HRR biomarker in the 2 cohorts presented. A discussion regarding other PARPis and BRCA1/2 occurs
Meredith Regan and David McDermott try to make sense of it all but are unexpectedly interrupted. PFS2 and TFS are covered along with previously discussed endpoints.
After the discussion with Mike Atkins, Bob Motzer gives his perspective of the 1st line renal cancer situation .
Prompted by a question during the oral kidney cancer session at ASCO, Mike Atkins explains his position. Disagreement prevails.
Mike is quizzed on his controversial comments at ASCO23 renal session. David McDermott joins in. We have edited the sound from the 1st version as it was poor - hope you like it better.
Toni Choueiri describes the results of this renal cancer trial exploring rechallange with immune therapy
Nick James describes the success this practice changing multi arm prostate study with an adaptive design
Josh Meeks describes his teams Nature Communications paper (including 11 supplementary figures).
Tom, who failed to invite a guest, quizzes Brian on the new data from the meeting he attended.
Danny Heng describes the history of this prognostic criteria and how it evolved into a predictive tool.
Karine Trindade e Fernando Maluf dão uma visão geral da reunião e dos avanços na investigação do câncer no Brasil
Toni Choueiri and Brian Shuch discuss Belzutifan alone and in combination VHL and advanced disease.
Michiel van der Heijden describes his Nature Medicine paper and talks about whether he enjoyed ASCO
The Uromigos are joined by Daniel George, MD, to review RCC and prostate cancer presentations from the 2023 ASCO GU Cancers Symposium, including triplet versus doublet therapy, the ARASENS trial, and the ZIRCON phase 3 trial. Dr. George is a medical oncologist at Duke Health, specializing in genitourinary malignancies.
Pavlos Msaouel discusses some of the statistical components of this and other RCC studies.
Silke Gillessen and Nick James discuss the results of this randomised trial exploring duration of adjuvant/salvage androgen ablation with XRT in prostate cancer.
Here are the details for the Livestream portions of The Uromigos Nashville meeting!
Bladder Cancel Panel on September 30, 1-2PM CST https://youtu.be/yzYkYZbCguE
Prostate Cancer on October 1, 10-11AM CST https://youtu.be/WghMP5kcqxQ
RCC Panel on October 1, 2-3PM CST https://youtu.be/4-DQ6lghQ2o
Martin Stockler describes this paper, which shows mixed effects of enza on QOL in prostate cancer.
Yelena Janjigian describes ipi/nivo vs nivo chemo vs chemo in Gastric cancer - published in Nature
Pete Nelson describes mechanism of action and current clinical application in prostate cancer
Alfonso Gómez & Guillermo de Velasco describir los aspectos más destacados de esta reunión en español
Laurence Albiges gives an overview of the new ESMO RCC guidelines and Brian challenges her and Tom.
Tom, Brian and Chris discuss developments for Uromigos podcasts and growth for the future.
Peter Albers discusses three timely prostate cancer topics from the recent EAU meeting.
Grant Stewart gives his opinion on timely RCC surgical topics surrounding the European Association of Urology meeting
Karim Fizazi describes the results of this randomised, potentially practice-changing trial.
James Larkin describes learning from adjuvant immune checkpoint inhibitors in melanoma.
Dena Battle is the co-founder and president of KCure and a passionate kidney cancer patient advocate.
Dr. Lydia Makaroff, Vice President of the World Bladder Cancer Patient Coalition, discusses key issues for bladder cancer.
Jorge Garcia discusses the pembrolizumab and atezolizumab bladder cancer dangling accelerated approvals and the ODAC process
Viktor Grünwald discusses treatment for progression of disease after front lines PD1 based therapy.
Joaquim Bellmunt describes this study as well as adjuvant nivolumab and ctDNA in bladder cancer.
Everything you wanted to know about quality of life assessment in cancer but were too afraid to ask.
In these podcasts, we explore academic career development with individuals in different stages of their career.
In these podcasts, we explore academic career development with individuals at different stages in their career.
In these podcasts, we explore academic career development with individuals in different stages of their career.
These new data are important as it is the setting where these agents are currently recommended, but we have not seen the data in this specific subset until now.
Stephen Boorjian outlines his recent Lancet oncology paper.
Tom and Brian struggle to keep up.
Nick James and Chris Sweeney debate this issue. Tom and Silke try to keep things on track.
Piet Ost, Chris Sweeney and Silke Gillessen discuss controversies around the management of oligometastatic prostate cancer.
Matt discusses the year in review, including first line and adjuvant immune therapy studies, ADCs and FGFR targeting are also discussed.
Christian Kollmannsberger gets into the Christmas spirit by discussing highlights of 2020.
Kim Rathmell discusses this paper, which divides clear cell renal cancer into seven relevant subgroups. Brian askes an interesting question at one point.
David McDermott and Brian Rini debate treatment options in front line renal cancer. It's hard to identify any winners from this podcast.
Pam Sharma and Michiel Van Der Heijden discuss neoadjuvant PD(L)1 + CTLA4 inhibition in urothelial cancer.
Gretchen Vaughan, Kidney Cancer Association CEO, discusses the upcoming International Kidney Cancer Symposium meeting and KCA's grant program. Tom and Brian review some of the top abstracts.
'New Drugs vs New Biomarkers' Bill Kaelin (Nobel Laureate) vs Tom Powles (keen cyclist), extend their discussion from KCRS20 in the 2nd Uromigos Debate.
Dr. Peter O'Donnell and Prof. Tom Powles debate front line treatment options in urothelial cancer.
A large randomised investigator-initiated Alliance study gives insight in to perioperative treatments for high risk prostate cancer.
Nick gives us a quick summary of the STAMPEDE study and gives an overview of the latest data.
AMG 160; a half-life extended (HLE) bispecific T-cell engager (BITE®) antibody construct is discussed as is the future of immune therapy in CRPC.
Chris Sweeney (last author) discusses the ATK inhibitor Ipatercertib in pTEN altered CRPC. A positive R3 trial in the ESMO plenary session.
The group try to get to the bottom of whether these data has made any difference in treatment and future plans.
Andrea talks about her phase 2 trial which shows activity for Cabozantinib in urothelial cancer.
Tom, Brian and Chris Sweeney discuss the challenges of development of biomarkers for immune therapy in bladder cancer.
Jan Oldenburg from Norway discusses treatment choices for stage 1 testis cancer, the dilemma of high dose therapy for relapse and long term toxicity of chemotherapy.
Axel Bex talks about small renal masses, robotic vs partial nephrectomy and surgery in metastatic disease.
The World Tour stays in Germany to discuss the first line renal cancer (clear cell and non-clear cell) and clinical trials with Oliver Grimm.
Jürgen discusses German research and surgery for bladder cancer. The podcast ends abruptly - which was not his fault!
Cristina Suarez discusses the success of clinical trials in Spain, and access to treatments.
Yoshi Tomita explains treatment pathways and research in GU cancer in Japan. Brian explains why he likes Japan so much.
Ian Davis discusses why ANZUP has been so successful, and the EnzaMet study. An uninvited guest arrives towards the end.
Juan Sade discusses research, treatment pathways in GU cancer, steak and red wine in Argentina.
The tour lands in sunny Brazil with a trip to a Japanese restaurant and a discussion about research and prostate cancer.
The Uromigos World Tour moves to Paris. Treatment for tumours that progress after first line immunetherapy is discussed. The role of Tivozanib is a focus for the dialogue.
Danny discusses Italian food and the past, present and future of the IMDC prognostic score.
Peter Black talks about his recent BCG refractory NMIBC ASCO presentation and its implications for the field.
Tian Zhang discusses three ASCO bladder cancer abstracts with immune therapy/targeted therapy combinations
Dr. Kala Sridhar, Professor Tom Powles and Dr. Brian Rini discuss the data presented at ASCO.
Dr. Toni Choueiri discusses the results of this study, which appears to show a survival signal, but it is difficult to interpret.
Joaquim Bellmunt explains a bit about why this trial was not successful and what it means for the field.
Mike Atkins describes the results of this study which helps shed light on the role of ipilimumab and nivolumab in this disease.
Betsy Plimack discusses the updated data with a minimum of 23 months' follow up. Dr. Brian Rini and Professor Tom Powles asks what it adds.
Eric Jonasch discusses his ASCO presentation, which shows significant activity of HIF targeting in renal cancer patients with VHL syndrome.
Jeremy Warner summarises the recent Lancet paper describing the outcome of cancer patients with COVID-19.
Joaquim Bellmunt talks about management of muscle invasive bladder cancer prior to the Atezolizumab adjuvant data at ASCO20.
Kaushik Amancherla and Javid Moslehi discuss the link of COVID-19 and cardiovascular disease. Professor Tom Powles and Dr. Brian Rini struggle to keep up.
The Uromigos struggle to describe what cancer care looks like in three months’ time during the COVID-19 pandemic.
The Uromigos can’t agree on how to approach COVID-infected GU cancer patients who need systematic treatment.
Professor Monty Pal discusses non-clear cell renal cancer while Dr. Brian Rini gets irritated by background interruptions.
Dena Battle presents a 500-patient survey on issues around COVID-19. Professor Tom Powles and Dr. Brian Rini attempt to address the issues raised.
Professor Tom Powles, Dr. Brian Rini and Dr. Toni Choueiri discuss the evolving landscape in Boston, and meetings such as ASCO and ESMO in 2020.
Professor Nick Mark discusses the latest data on drug treatments and trials for COVID-19.
The Uromigos discuss the practicalities in surgery for bladder cancer in the era of COVID-19 with Betsy Plimack (Fox Chase Cancer Center, Philadelphia)
Dr. Brian Rini and Professor Tom Powles discuss the data and ongoing studies with the IL-6 antibody tocilizumab.
A discussion with doctors from the Fred Hutchinson Cancer Center in Seattle about COVID-19.
Chuck Drake and Doug Johnson discuss possible risk benefits of immune checkpoint inhibitors during the COVID-19 pandemic.
Dena Battle (President, KCCure) asks key patient-focused questions about kidney cancer management during the COVID-19 pandemic.
Five members of the groups from Europe and North America discuss the current situation for cancer patients.
Silke Gillessen and Chris Sweeney discuss how data from recent ESMO and GU ASCO meetings has changed the way they treat prostate cancer.
In this episode, Professor Tom Powles and Dr. Brian Rini talk to Dr. Kala Sridhar about key developments in urothelial cancer presented at ASCO GU 2020.
Dr. Brian Rini and Professor Tom Powles ask David McDermott about how he chooses between ipilimumab/nivolumab or axitinib/pebrolizumab intreatment options
Professor Tom Powles and Dr. Brian Rini discuss the purpose of the podcasts and how to complain if you don’t like them
Matthew Galski and Petros Grivas engage in a discussion with Professor Tom Powles and Dr. Brian Rini about IMVIGOR130.
Guests Dr. Arjun Balar and Professor Seth Lerner give an overview of the recent FDA approval of pembrolizumab in this indication to Professor Tom Powles and Dr. Brian Rini.